RIGL vs VSTM
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RIGL · Rigel Pharmaceuticals$40.09 ▼ 2.67%
VSTM · Verastem$6.33 ▼ 7.73%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RIGL -19.5%
- VSTM -35.7%
Head to head
| Metric | RIGL | VSTM |
|---|---|---|
| Price | $40.09 | $6.33 |
| Change today | ▼ 2.67% | ▼ 7.73% |
| Market cap | $754.89M | $797.67M |
| Return, 3 months | -11.1% | -7.7% |
| Return, year to date | -6.4% | -18.0% |
| Return, 1 year | -13.3% | -36.7% |
| P/E (TTM) | 2.5 | – |
| P/B | 1.7 | 79.1 |
| P/E percentile vs own 5y | 70th | 1st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +16.5% | +113.6% |
| Net profit growth (YoY) | -52.7% | +24.2% |
| Gross margin | 89.6% | 86.1% |
| Operating margin | 26.3% | -193.7% |
| Net margin | 106.6% | -178.4% |
| Return on equity | 109.2% | – |
| Analyst target vs. price | +66.5% | +192.3% |
| Analyst buy share | 50% | 100% |
| RSI (14) | 35 | 28 |
| 30-day volatility | 66.4% | 94.6% |
| Max drawdown, 1 year | -50.1% | -67.6% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- VSTM is the largest of the group by market value.
- RIGL has returned the most over the past year.
- VSTM is growing revenue fastest.
- RIGL keeps the most profit per dollar of sales.
- RIGL has been the calmest stock over the last 30 days.